BMRN 250117 67.50C (BMRN250117C67500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

BMRN250117C67500

Watchlist

1.25
-1.55-55.36%

15min DelayClose Jan 10 16:00 ET

1.25High1.25Low

Intraday

5D
Daily

News

Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators
BenzingaJan 8 14:32 ET
Shareholders Should Be Pleased With BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Price
Simply Wall StJan 8 12:37 ET
Bernstein Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $90
Moomoo NewsJan 8 03:33 ET · Ratings
Bernstein Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)
TipRanksJan 8 01:45 ET · Ratings
Zacks.com Featured Highlights Include Leidos, Amazon.com, Halozyme Therapeutics and BioMarin Pharmaceutical
Yahoo FinanceJan 7 05:18 ET
Express News | Biomarin Pharmaceutical Inc : BofA Global Research Cuts Price Objective to $100 From $101
ReutersJan 6 08:44 ET

Comments

Moomoo AI

Mar 25, 2024 07:52

Recent insider selling at BioMarin Pharmaceutical raises caution despite high insider ownership. The history of share sales is concerning, though the company's earnings growth is positive.

Insiders At BioMarin Pharmaceutical Sold US$6.7m In Stock, Alluding To Potential Weakness

Moomoo AI

Mar 7, 2024 07:41

BioMarin's CEO, Alexander Hardy, expressed confidence in Hubbard's leadership and expertise in lifecycle management and delivering growth across multiple therapeutic areas. He anticipates that her deep experience in the biopharmaceutical industry will add to the talent within the organization.

Press Release: BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer

Moomoo AI

Feb 8, 2024 08:52

BioMarin Pharmaceutical Inc.'s low P/S ratio may be due to its sluggish growth forecast. The market's expectation of continued poor revenue growth could be suppressing the P/S. Shareholders' pessimism on the company's revenue prospects seems to be the main contributor to the depressed P/S.

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Share Price Is Matching Sentiment Around Its Revenues

Moomoo AI

Jan 18, 2024 06:34

BioMarin Pharmaceutical's decent earnings growth and high rate of reinvestment are positive, despite low ROE. However, earnings growth could have been higher with improved ROE. Forecasts reveal expected earnings acceleration.

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Moomoo AI

Dec 21, 2023 10:14

Analysts see M&A as integral to BioMarin's value creation. Clarity on the market potential of Roctavian could stimulate transactional activities. A gene therapy division spin-off followed by a business sale is anticipated.

BioMarin May Be More of an M&A Target With Activist Elliott Pact - Analysts